Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Eovist Clear all
Withdrawn Early Phase 1 Interventional

24hr Imaging Of HCC After EOVIST

NCT01968629
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Eovist
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Is Eovist Suitable for Arterial-Phase MR Imaging of Liver

NCT02684526
View directory record Official record
Conditions
Liver Disease
Interventions
Eovist Contrast, Non Eovist Contrast
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
21 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 25, 2026, 4:53 AM EDT
Not listed Early Phase 1 Interventional

Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

NCT03960788
View directory record Official record
Conditions
Cancer of the Prostate, Castration-resistant Prostate Cancer
Interventions
Gadoxetate Sodium
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 25, 2026, 4:53 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Gadopiclenol vs Gadoxetate MRI for Liver Lesions

NCT06596616
View directory record Official record
Conditions
Liver Lesion
Interventions
Radiology, Gadopiclenol
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Completed No phase listed Observational

Functional MRC With Eovist for Acute Cholecystitis

NCT02100358
View directory record Official record
Conditions
Acute Cholecystitis
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Early Phase 1 Interventional

68 Ga PSMA PET/MRI for Hepatocellular Carcinoma

NCT03982407
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
68Ga-PSMA-11 PET/MRI
Drug
Lead sponsor
Ajit H. Goenka, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 25, 2026, 4:53 AM EDT
Recruiting Phase 4 Interventional

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

NCT04373564
View directory record Official record
Conditions
Motor Function, Cognitive Function, Contrast Media
Interventions
Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol
Procedure · Drug
Lead sponsor
Guerbet
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

NCT07223307
View directory record Official record
Conditions
Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC
Interventions
MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium

NCT01783314
View directory record Official record
Conditions
Hepatic Fibrosis
Interventions
MRI of liver
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 25, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

NCT06265272
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions
Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer

NCT02578602
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage 0 Adult Hepatocellular Carcinoma, BCLC Stage A Adult Hepatocellular Carcinoma, BCLC Stage B Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Localized Resectable Adult Liver Carcinoma
Interventions
Gadoxetate Disodium, Magnetic Resonance Imaging
Drug · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 25, 2026, 4:53 AM EDT
Completed No phase listed Observational Results available

Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.

NCT01043523
View directory record Official record
Conditions
Liver Neoplasms, Adenoma, Carcinoma, Liver Abscess
Interventions
Gadoxetic Acid Disodium (Eovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Months to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Palo Alto, California • New York, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 25, 2026, 4:53 AM EDT
Not listed Not applicable Interventional

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

NCT01082224
View directory record Official record
Conditions
Liver Cancer
Interventions
iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
Drug · Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 4 Interventional

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

NCT04288323
View directory record Official record
Conditions
Liver Cancer, Liver Cirrhoses, Liver Carcinoma
Interventions
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Not listed No phase listed Observational

Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents

NCT01341132
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
MRI Scan of the Liver enhanced with Eovist
Procedure
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Oct 25, 2026, 4:53 AM EDT
Terminated Phase 4 Interventional Results available

Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases

NCT04973007
View directory record Official record
Conditions
Oligometastatic Disease, Liver Metastases, Colorectal Cancer
Interventions
Gadoxetate disodium, Gadobenate dimeglumine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Not yet recruiting No phase listed Observational

PET/MRI of Primary Sclerosing Cholangitis

NCT06252610
View directory record Official record
Conditions
PSC
Interventions
Radiotracer Injection, Contrast Media, Magnetic Resonance, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Completed No phase listed Observational

Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration

NCT02226666
View directory record Official record
Conditions
Liver Tumor
Interventions
MRI with Multihance, MRI with Eovist
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 25, 2026, 4:53 AM EDT
Active, not recruiting Not applicable Interventional

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

NCT02156739
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver and Intrahepatic Bile Duct Disorder, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Gadobutrol, Gadoxetate Disodium
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

NCT06905054
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
Interventions
Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer

NCT06130280
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases
Interventions
MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 25, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional Results available

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

NCT02084628
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Primovist / Eovist in Renally Impaired Patients

NCT00908596
View directory record Official record
Conditions
Contrast Media
Interventions
Gadoxetic acid disodium (Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Honolulu, Hawaii + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

NCT01867424
View directory record Official record
Conditions
Prostate Cancer
Interventions
Eovist
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 25, 2026, 4:53 AM EDT